A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation ; volume:11 ; number:1 ; day:21 ; month:2 ; year:2011 ; pages:1-11 ; date:12.2011
BMC cancer ; 11, Heft 1 (21.2.2011), 1-11, 12.2011
- Creator
-
Valentine, Jane M.
- Contributor
-
Kumar, Sonia
Moumen, Abdeladim
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-11-79
- URN
-
urn:nbn:de:1111-2016030365205
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Valentine, Jane M.
- Kumar, Sonia
- Moumen, Abdeladim
- SpringerLink (Online service)
Other Objects (12)
Targeting MDM2, the antagonist of the tumor suppressor p53
Mdm2 requires Sprouty4 to regulate focal adhesion formation and metastasis independent of p53
Evolution of the p53-MDM2 pathway
p73ΔN antagonist to the tumor suppressor p53 and independent regulator of transcription
Small-Molecule Inhibitors of p53-MDM2 interactions
MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner
A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation
Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Correction: MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
Targeting MDM2, the antagonist of the tumor suppressor p53
Mdm2 requires Sprouty4 to regulate focal adhesion formation and metastasis independent of p53
Evolution of the p53-MDM2 pathway
p73ΔN antagonist to the tumor suppressor p53 and independent regulator of transcription
Small-Molecule Inhibitors of p53-MDM2 interactions
MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner
A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation
Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Correction: MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
Targeting MDM2, the antagonist of the tumor suppressor p53
Mdm2 requires Sprouty4 to regulate focal adhesion formation and metastasis independent of p53
Evolution of the p53-MDM2 pathway
p73ΔN antagonist to the tumor suppressor p53 and independent regulator of transcription
Small-Molecule Inhibitors of p53-MDM2 interactions
MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner
A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation
Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Correction: MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials